Kestra Advisory Services LLC grew its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK – Free Report) by 9.4% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 186,862 shares of the pharmaceutical company’s stock after acquiring an additional 16,031 shares during the quarter. Kestra Advisory Services LLC’s holdings in GSK were worth $9,001,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in GSK. Security National Bank of SO Dak bought a new position in GSK in the second quarter worth about $38,000. Laurel Wealth Advisors LLC purchased a new position in shares of GSK during the 3rd quarter worth approximately $36,000. Trust Co. of Vermont purchased a new position in shares of GSK in the 2nd quarter valued at approximately $54,000. Provenance Wealth Advisors LLC boosted its position in shares of GSK by 378.8% during the third quarter. Provenance Wealth Advisors LLC now owns 1,149 shares of the pharmaceutical company’s stock valued at $55,000 after purchasing an additional 909 shares in the last quarter. Finally, Philadelphia Investment Partners LLC purchased a new stake in GSK in the second quarter worth $70,000. 15.74% of the stock is currently owned by institutional investors.
GSK Price Performance
NYSE GSK opened at $51.27 on Wednesday. The stock has a market capitalization of $103.70 billion, a price-to-earnings ratio of 17.81, a PEG ratio of 2.32 and a beta of 0.28. GSK PLC Sponsored ADR has a 1-year low of $45.81 and a 1-year high of $61.69. The company has a debt-to-equity ratio of 1.18, a current ratio of 0.86 and a quick ratio of 0.56. The business’s fifty day moving average price is $49.30 and its 200-day moving average price is $52.39.
GSK Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 7th. Shareholders of record on Friday, November 13th will be given a $0.4518 dividend. The ex-dividend date is Friday, November 13th. This is a boost from GSK’s previous quarterly dividend of $0.4515. This represents a $1.81 annualized dividend and a yield of 3.5%. GSK’s payout ratio is 61.46%.
Analyst Ratings Changes
GSK has been the topic of a number of research reports. Berenberg Bank restated a “buy” rating on shares of GSK in a report on Tuesday, October 6th. Barclays reiterated a “sell” rating on shares of GSK in a report on Monday, September 7th. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a research report on Tuesday, August 25th. Citigroup began coverage on GSK in a research note on Friday, July 24th. They set a “neutral” rating for the company. Finally, Sanford C. Bernstein reissued a “buy” rating on shares of GSK in a research note on Sunday, August 2nd. Three investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $56.30.
Check Out Our Latest Research Report on GSK
GSK Profile
GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.
Featured Stories
- Five stocks we like better than GSK
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK – Free Report).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
